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Abstract Polyisoprenoid alcohols are membrane lipids that
are present in every cell, conserved from archaea to higher
eukaryotes. The most common form, alpha-saturated poly-
prenol or dolichol is present in all tissues and most organelle
membranes of eukaryotic cells. Dolichol has a well defined
role as a lipid carrier for the glycan precursor in the early
stages of N-linked protein glycosylation, which is assembled
in the endoplasmic reticulum of all eukaryotic cells. Other
glycosylation processes including C- and O-mannosylation,
GPI-anchor biosynthesis and O-glucosylation also depend on
dolichol biosynthesis via the availability of dolichol-P-
mannose and dolichol-P-glucose in the ER. The ubiquity of
dolichol in cellular compartments that are not involved in
glycosylation raises the possibility of additional functions
independent of these protein post-translational modifications.
The molecular basis of several steps involved in the synthesis
and the recycling of dolichol and its derivatives is still
unknown, which hampers further research into this direction.
In this review, we summarize the current knowledge on
structural and functional aspects of dolichol metabolites. We
will describe the metabolic disorders with a defect in known
steps of dolichol biosynthesis and recycling in human and
discuss their pathogenic mechanisms. Exploration of the
developmental, cellular and biochemical defects associated
with these disorders will provide a better understanding of the
functions of this lipid class in human.
Structure of dolichol metabolites and their tissue
and subcellular distribution
Polyisoprenoid alcohols are membrane lipids present in
every cell, from archaea to higher eukaryotes. They all have
in common a function as sugar carrier for protein
glycosylation but display a surprising structural diversity
between different species and also inside the same organism
(Swiezewska and Danikiewicz 2005; Jones et al. 2009).
The most common species, dolichol was originally identified
by Pennock, Hemming and Morton in 1960 (Pennock et al.
1960). Dolichol phosphate requirement for glycoprotein
biosynthesis was established 10 years later by Behrens and
Leloir (Behrens and Leloir 1970). During dolichol biosyn-
thesis, isoprenoids are used as a five-carbon building block
to generate linear polymers. These polyisoprenoids are not
present as species of a single chain length, but are found as a
mixture (or family) of four or more different chain lengths,
with one or two chain lengths predominating. The size of
dolichols (i.e., the mixture of different chain lengths) is
variable depending on the species. In the yeast S.cerevisiae,
the size ranges from 14 repeating isoprene units to 18 (Dol-14
to Dol-18) and the major dolichols are Dol-16 and Dol-17. A
preponderance of Dol-19 has been observed for several
vertebrates including human (Chojnacki and Dallner 1988).
Whereas the length of these lipids is variable, the
configuration of the double bonds of polyisoprenoids is
fixed. All dolichol species characterized so far show a
di-trans, poly-cis configuration. This is a consequence of
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trans-prenyl transferase and a long-chain cis-prenyl trans-
ferase (Skorupinska-Tudek et al. 2008). The α-terminal
isoprene unit is unsaturated in polyprenol (formerly
dehydrodolichol), whereas dolichol contains a saturated α-
terminal unit (See Fig. 2). This saturation event is of great
interest because it is absent in bacteria but required in many
eukaryotic cells (Krag 1998). The terminal hydroxyl group
of dolichol may exist either free, phosphorylated or
esterified with fatty acids. Depending on the tissue or
membrane, dolichyl esters represent 10 to 60% of the total
dolichol content and Dol-P in general represents less than
10% (Tollbom and Dallner 1986).
Dolichol biosynthesis is known to occur mainly on the
cytoplasmic face of the ER, where N-glycosylation occurs.
Besides the presence of glycosylated dolichol species in the
ER, dolichol is present in all subcellular membrane systems.
The free alcohol, but also phosphorylated and esterified
dolichol are detected in peroxisomes and are highly enriched
in lysosomes, plasma membrane and Golgi vesicles (Rip et
al. 1981). The ER microsomal fraction is low in dolichol
compared to other organelles. The mitochondrial membranes
and nuclei also contain a limited amount of dolichol,
especially low in the mitochondrial inner membrane.
All tissues and almost all membranes in eukaryotic cells
contain dolichol. In general, they are present in small
absolute quantities, only a few percent compared to
glycerol-based phospholipids (Chojnacki and Dallner
1988). However, the amount is highly variable depending
on tissue and age (Rip et al. 1985). For example, in human
endocrine tissues, this lipid is present in milligram
quantities per gram of wet weight, as much as phospholipids.
In different species, several organs are highly enriched in
dolichol. In human, testes and especially pituitary are
associatedwithhighcontentsofdolichol.Surprisingly,human
tissues seem to have levels 5 to 10-fold higher in comparison
to the corresponding tissues from rat or mouse, ranging from
~0.1-2 mg/g fresh weight in human versus ~10-200 μg/g in
mouse orrat (RipandCarroll 1985). Dolichol is also detected
in the serum at low concentration, associated with the HDL
fraction (Elmberger et al. 1988).
The reason of the specific enrichment of some tissues
versus others is unknown, but does not seem to be correlated
with the level of glycosylation.
A significant age-related accumulation of dolichol has
been reported. In the human brain, a 100-fold increase has
been detected during the aging process (Pallottini et al.
2003), a similar increase has been observed in other tissues.
These accumulations might also be involved in pathology
as elevated dolichol levels have been detected in hepato-
carcinogenesis and ceroid lipofuscinosis (Ericsson et al.
1993). However, this accumulation seems to be disrupted in
Alzheimer’s disease as a significant reduction of dolichol
levels has been detected in patient brains (Edlund et al.
1994).
Cellular functions of dolichol
Phosphorylated dolichol has a well defined role as a lipid
carrier for the glycan precursor in the early stages of N-
linked protein glycosylation. This precursor is assembled in
the endoplasmic reticulum of all eukaryotic cells (Fig. 1).
During N-linked protein glycosylation, a first dolichol
phosphate is used by the GlcNAc-1-phosphotransferase to
start the assembly of the lipid-linked oligosaccharide (LLO)
on the cytoplasmic face of the ER. The product of this
reaction is elongated to Man5GlcNAc2-P-P-Dol and then
flipped to the inside of the ER. Then four other dolichol
phosphates, previously linked to a mannose (Man-P-Dol)
and flipped inside the ER lumen, are used as sugar donor
for LLO synthesis. Finally, three dolichol phosphates in the
form of dolichol phosphate glucose (Dol-P-Glc) as sugar
donor are used for completion of the LLO before transfer of
the glycan onto nascent proteins (Fig. 1). In addition to its
role during LLO biosynthesis, Man-P-Dol is a necessary
substrate for C- and O-mannosylation as well as GPI anchor
biosynthesis (Rosenwald et al. 1990).
In comparison to dolichol phosphate, the role of the free
alcohol and its carboxylic ester is less established. An
important question is the effect of these lipids on the
physical properties of biological membranes. Biophysical
studies have shown that dolichol and dolichol phosphates
destabilize the bilayer structure of model membranes, and
also increase their fluidity (Valtersson et al. 1985). Isolated
membrane phospholipids may adopt different phases
including the lamellar bilayer phase and a phase where
phospholipids are arranged as cylinders with the lipid head
group facing the inner core of the cylinder, also called
hexagonal phase II (Turned and Gruner 1992). Dolichol
promotes this hexagonal phase II organization, which may
facilitate movements between the two layers of the
membrane and may elicit the transmembrane movement
of LLOs. This property would add another function for this
lipid in the glycosylation process. Another interesting
property is the fact that dolichol enhances vesicle fusion
and that dolichol phosphate stimulates the fusion of rat liver
microsomes (van Duijn et al. 1986). In this way, dolichol
might play a more general role in membrane trafficking. In
vivo, consequences of dolichol synthesis defects have been
investigated in a yeast mutant for the cis-isoprenyltransferase
(cis-IPTases) RER2 responsible for the elongation of the
polyisoprenoid chain (Sato et al. 1999) (Belgareh-Touze et
al. 2003). These studies suggest that free dolichol is involved
in vesicle trafficking, a function in agreement with an
enrichment of the Golgi apparatus for this lipid.
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established. Besides an effect on membrane properties, the
esterified form was suggested to be necessary for intracel-
lular dolichol transport (Tollbom and Dallner 1986;
Turunen and Schedin-Weiss 2007). An oxidized derivative
of dolichol, dolichoic acid has also been identified in
human brain (Ward et al. 2007). It is speculated to result
from dolichol catabolism (Van Houte et al. 1997), but its
exact function is unknown.
De novo synthesis of dolichol and recycling
The first steps in the biosynthesis of dolichol are common
with those for cholesterol and belong to the mevalonate
pathway (Fig. 2). This pathway starts with the condensation
of acetyl-CoA, followed by the production of mevalonate
through the action of HMG-CoA reductase (Swiezewska and
Danikiewicz 2005). After several modifications, isopentenyl
pyrophosphate (IPP) is produced. IPP condensation gives
rise to farnesyl pyrophosphate (FPP), used as the substrate of
many reactions including the synthesis of cholesterol,
dolichol, solanesyl pyrophosphate (i.e., the side chain of
ubiquinone) and for isoprenylation of proteins.
Elongation step
Cis-IPTases catalyse the synthesis of polyprenol pyrophos-
phate by sequential head-to-tail cis addition of multiple
molecules of IPP to farnesyl pyrophosphate (FPP). This is
Fig. 1 Dolichol cycle in the endoplasmic reticulum in human. The
Dol-P pool available for glycosylation reactions originates from de
novo synthesis of dolichol phosphate and its recycling from the
lumenal leaflet to the cytoplasmic leaflet of the ER. Cellular functions
of dolichol are indicated including known functions in N-
glycosylation (1–2), O-mannosylation (3), GPI-anchor biosynthesis
(4) and suspected effects on membrane biophysical properties (5–6).
Abbreviations: FPP, farnesyl pyrophosphate; DHDDS, dehydrodo-
lichyl diphosphate synthase; SRD5A3, steroid 5-alpha reductase 3;
DOLK, dolichol kinase; DPM1-3, dolichyl-phosphate mannosyltrans-
ferase polypeptide 1–3; MDPU1, mannose-P-dolichol utilization
defect 1; ALG5, asparagine-linked glycosylation 5; DOLPP1, dolichyl
pyrophosphate phosphatase 1; LLO, lipid-linked oligosaccharide
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on the cytoplamic side of the ER. At least two enzymes are
involved in this process in yeast (i.e., RER2 and SRT1). In
mammals only one cis-IPTase has been characterized
(Shridas et al. 2003). However, some other uncharacterized
or partially characterized enzymes might be involved. For
example, the human protein NUS1, homolog of the yeast
nuclear undecaprenyl pyrophosphate synthase 1, shares
significant sequence homologies with cis-IPTs. Structural
analysis of these enzymes (Takahashi and Koyama 2006)a s
well as functional studies in yeast (Sato et al. 1999) indicate
that cis-IPTs themselves determine the chain length of their
products. This was illustrated in a recent study from Rush et
al. (Rush et al. 2010) where the yeast cis-IPTase was
replaced by a bacterial one, resulting in the synthesis of a
dolichol with the length of the bacterial polyisoprenoid (i.e.,
11 units instead of 14–18 units). An intriguing aspect of
these cis-IPTases is the absence of a predicted transmem-
brane domain in their sequence despite their ER localiza-
tion. This might be explained by the existence of unknown
membrane protein interactors.
Dephosphorylation step
This step is supposed to occur between the elongation
process and the reduction step. Polyprenol pyrophosphate
phosphatase and polyprenol phosphatase activities have
been reported in whole-cell homogenates (Wolf et al.
1991), however, the molecular basis supporting these
enzymatic reactions is unknown. A dolichol pyrophosphate
phosphatase has been identified in yeast (CWH8)( F e r n a n d e z
et al. 2001). This enzyme is involved in the recycling of
dolichol after oligosaccharide transfer to a protein, by
removing one phosphate from Dol-PP in the ER (Fig. 1).
Fig. 2 De novo biosynthesis of
dolichol phosphate in human.
Polyisoprenoids are generated
by the condensation of iso
pentenyl pyrophosphate (IPP)
and dimethylallyl pyrophos-
phate (DMAPP), the 5-carbon
building blocks of all iso
prenoids. The mevalonate path-
way is responsible for the
synthesis of IPP and DMAPP.
The first step dedicated to doli-
chol biosynthesis is the elonga-
tion of farnesyl pyrophosphate
by the dehydrodolichyl diphos-
phate synthase (DHDDS) . This
cis-prenyl transferase uses IPP
as substrates to produce poly-
prenol pyrophosphate. It is
believe that this polyprenol
pyrophosphate is then dephos-
phorylated into polyprenol
before its reduction by
SRD5A5. Finally, the dolichol
kinase (DOLK) transfers a
phosphate from CTP to dolichol
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the regulation of the dolichol phosphate pool available for
the different glycosylation pathways (Schenk et al. 2001).
An alternative hypothesis suggests that the terminal
event of the elongation process could be the condensation
of a molecule of isopentenol instead of IPP (Ekstrom et al.
1987), avoiding a final dephosphorylation and reduction
event.
Reduction step
Several mutant cell lines defective for this step have been
identified, including Chinese hamster ovary cell (CHO)
mutants belonging to the same complementation group
lec9. They were identified based on lectin resistance and
present a general hypoglycosylation of proteins associated
with a reduced amount of mature LLO (Rosenwald and
Krag 1990). These mutants show a similar phenotype with
an accumulation of polyprenols of a chain length identical
to dolichols usually present in these cells, but lacking the
saturation of the alpha-isoprene unit. Polyprenols are
obligatory intermediates for the synthesis of dolichols and
are detected in large amount during in vitro biosynthesis of
dolichol. However, in vivo, polyprenol levels are usually
very low, often undetectable (Ekstrom et al. 1987; Sagami
et al. 1993), probably the result of a fast conversion to
dolichols. A mutant cell line from Trypanosoma Brucei
shows similar biochemical defects including the hypogly-
cosylation of proteins and the accumulation of polyprenol
(Acosta-Serrano et al. 2004). These CHO and Trypanosoma
mutants have in common a defect only partial in dolichol
biosynthesis, still present in these cells, and an unknown
genetic basis for this defect.
We reported recently the identification of the first
enzyme associated with this reduction step. This enzyme,
SRD5A3 in human and DFG10 in S.cerevisiae, shows
homology with steroid 5-alpha reductase enzymes (Cantagrel
et al. 2010). Mutation in the corresponding genes results in a
partial block of dolichol biosynthesis with an accumulation
of polyprenol and hypoglycosylation of proteins. Human
SRD5A3 can correct the phenotype of the yeast deleted for
DFG10 by preventing the accumulation of polyprenols and
the hypoglycosylation of carboxypeptidase Y (CPY). Muta-
tions associated with this defect in human are mostly
homozygous early truncating mutations, resulting in some
cases in non-sense mediated mRNA decay. These observa-
tions suggest that null alleles are responsible for this
condition. In yeast, the dfg10 deletion mutant is also only
partially blocked in this reduction step with an important
decrease in dolichol (i.e., a 70% decrease was detected
(Cantagrel et al. 2010)) associated with polyprenol accumu-
lation. These results reveal an unexpected alternative
pathway for dolichol synthesis, probably conserved from
yeast to human. The identification of these SRD5A3/DFG10
genes may be a starting point to look for physical and
genetic interactors in order to understand better the coupling
of this reduction step with polyprenol pyrophosphate
elongation and dephosphorylation as well as the nature of
the alternative pathway involved in the polyprenol reduction
step.
Phosphorylation step
The availability of dolichol phosphate is one of the rate-
limiting factors controlling the synthesis of LLOs in
eukaryotic cells (Carson et al. 1981; Spiro and Spiro
1986). Dolichol Kinase (DOLK) is a CTP-dependent
enzyme localized in the ER with a catalytic site oriented
to the cytoplasmic side of the ER (Shridas and Waechter
2006). The yeast gene encoding for the dolichol kinase is
essential, the phenotype resulting from a mutation of this
gene was studied with the temperature sensitive mutant
sec59 (Heller et al. 1992). In this mutant, Dol-P levels are
less than 10% of wt yeast at restrictive temperature. This
reduced availability of Dol-P results in incomplete glyco-
sylation of secretory proteins and strongly affects O-
mannosylation and GPI anchor synthesis (Heller et al.
1992).
Dolichol recycling
After the transfer of the oligosaccharide to nascent proteins,
Dol-P-P is released in the lumenal leaflet of the ER (Fig.1).
After one dephosphorylation step mediated by DOLPP1,
Dol-P returns directly to the cytoplasmic leaflet where it
can be re-used for LLO biosynthesis (Rush et al. 2008). The
human DOLPP1 gene is the predicted ortholog of the
CWH8/CAX4 yeast gene. The functional conservation
through evolution was tested with the mouse gene Dolpp1
(Rush et al. 2002). In yeast, a defect in recycling Dol-P-P
from the lumenal to the cytoplasmic leaflet of the ER
impairs protein N-linked glycosylation (van Berkel et al.
1999; Fernandez et al. 2001). This indicates that this
recycling of Dol-P-P contributes significantly to the pool
of Dol-P available for glycosylation reactions.
Human disorders affecting the dolichol cycle
Phenotypes resulting from dolichol biosynthesis defects
Defects in the biosynthesis of N-glycans lead to diseases
known as congenital disorders of glycosylation (CDG)
(Freeze 2006; Jaeken and Matthijs 2007; Haeuptle and
Hennet 2009). ResearchonCDGincreasesourunderstanding
of consequences of a defect in the dolichol cycle. Recently,
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sis (SRD5A3, DOLK) have been described, whereas other
defects are closely associated with dolichol metabolism
(MPDU1, DPM synthase). Unlike the disruption of genes
strictly involved in the N-glycosylation process, defects in
dolichol metabolism are predicted to affect several cellular
pathways (Denecke and Kranz 2009).
Recently, the most upstream defect in the mevalonate
pathway for dolichol-P synthesis was identified, it affects the
reductionofpolyprenoltodolichol.Inagroupofpatientswith
variable eye malformations, cerebellar vermis hypoplasia,
anemia, ichthyosiform dermatitis, liver dysfunction and
coagulation abnormalities, we recently identified loss of
function mutations in the SRD5A3 gene (SRD5A3-CDG;
CDG-Iq) (Cantagrel et al. 2010;M o r a v ae ta l .2010). The
12 patients originally reported have an abnormal N-
glycosylation profile of serum transferrin consistent with a
role of polyprenol reductase in N-glycosylation. The
transferrin isoelectric focusing shows a CDG type I profile
with increased levels of asialo- and disialotransferrin. A
family has also been reported without a clear diagnosis of
CDG based on a routine transferrin test (Kahrizi et al. 2011).
This observation might be the result of variabilities some-
times observed in CDG patients (Vermees et al. 2007)o r
might indicate that milder forms of this disorder can be
missed with routine transferrin isoelectric focusing.
A deficiency one step further of dolichol kinase
(MIM#610768;DOLK-CDG; CDG-Im) was describedinfour
children from two families who died in their 1
st year of life.
Clinical features included dry ichthyosiform skin, seizures,
severe muscular hypotonia, and progressive dilatative cardio-
myopathy. The reported homozygous missense mutations
almost abrogated the activity of the DOLK enzyme and were
not able to complement the yeast dolichol kinase mutant
(Kranz et al. 2007). Severe defects in N-glycosylation have
been demonstrated using IEF of transferrin but some aspects
of the phenotype might be caused by the involvement of
other pathways. It can be speculated that less severe
mutations in the DOLK gene can be responsible for a milder
phenotype.
Dolichol-P is subsequently converted into dolichol-P-
mannose for use as mannose donor in different ER glycosyl-
ation reactions. Mutations in the Dol-P-Man utilization
protein (MPDU1), required for the availability of Dol-P-
Man in the ER, lead to CDG-If. Four patients have been
described (Schenck et al. 2001; Kranz et al. 2001)w i t h
mutations in the MPDU1 gene, presenting with early onset
visual loss, seizures, psychomotor retardation and skin
abnormalities like ichthyosyform skin. In all patients, N-
glycosylation was found to be abnormal. Synthesis of Dol-P-
Man is carried out by the DPM-synthase complex, consisting
of DPM1-3 subunits. Mutations in DPM1 (CDG-Ie) were
found in children with severe congenital visual loss, optic
atrophy and seizures (Imbach et al. 2000; Kim et al. 2000),
and one of the children was diagnosed with congenital
frontal cortical hypoplasia (Garcia-Silva et al. 2004).
Although no muscle histology was reported, all patients
presented with hypotonia and increased CK. The relatively
mild DPM3 defect was characterized by muscle dystrophy
and dilated cardiomyopathy. Immunohistochemical analysis
indicated a defect in alpha-dystroglycan O-mannosylation
(Lefeber et al. 2009). No skin abnormalities were reported in
the DPM synthase deficient patients.
Evidence for N-glycosylation defects
DOLK-CDG and SRD5A3-CDG have in common a clear
defect in the ER part of the N-glycan biosynthesis (i.e.,
CDG type I). This defect is identified with the detection of
glycoproteins with unoccupied N-glycosylation sites, both
in patient serum and in the yeast models of these
conditions. Multiple factors influence the variable site
occupancy (Jones et al. 2005) including substrate concen-
trations. The pathophysiology of dolichol kinase and
polyprenol reductase deficiencies show overlapping features
with a likely effect on the Dol-P pool although it is less clear
for SRD5A3 defects.
DOLK deficiency impacts directly the pool of dolichol
phosphate, thereby limiting protein N-linked glycosylation
and other glycosylation pathways via reduced Dol-P-Man
formation. It is interesting to note that only a special pool
out of the total dolichol phosphate present in the ER
membrane is thought to participate actively in the glyco-
sylation process (Hubbard and Robbins 1980; Gao and
Lehrman 2002).
SRD5A3 deficiency may have an indirect effect on the
dolichol phosphate pool. In vitro, dolichol phosphate is the
limiting factor of LLO synthesis in cell extractsformSRD5A3
patient fibroblasts (Cantagrel et al. 2010). Although only a
small percentage of dolichol is converted to Dol-P, SRD5A3
may contribute directly to the dolichol pool available for
phosphorylation and LLO biosynthesis. With respect to the
minimal amount of dolichol in the ER, further research into
organelle specific effects of dolichol cycle defects will be
required to obtain further insights. In the case of polyprenol
reductase deficiency there is a clear accumulation of
polyprenol detected in yeast, mouse and to a lesser extend
in the serum of SRD5A3 patients. In these patients, serum
levels of dolichols and polyprenols were elevated resulting in
abnormal ratios of these lipids in favor of a block in the
conversion of polyprenols to dolichol (Cantagrel et al. 2010;
Morava et al. 2010). These serum polyisoprenoids are not
available for protein glycosylation and they could result from
regulation of cellular dolichol homeostasis. An intriguing
question is if this accumulating precursor can have a
deleterious effect on N-glycosylation or other cellular
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polyprenol phosphate can be used by mammalian glycosyl-
transferases for LLO synthesis (D'Souza-Schorey et al.
1994), however, these substrates are not as effective as
dolichol linked saccharides. It is not known if polyprenol can
have an inhibitory effect on other dolichol-binding enzymes.
Evidence for O-mannosylation defects
O-mannosylation defects result in muscular dystrophy with
elevated levels of creatine kinase and can be associated
with varying degrees of cerebral cortex malformations,
visual abnormalities and dilated cardiomyopathy. No
muscular dystrophy has been detected in SRD5A3 patients
and creatine kinase levels were normal when tested. Brain
imaging revealed cerebellar vermis hypoplasia as the main
feature in SRD5A3 patients whereas imaging of DOLK
patients did not detect any malformations. A comparison
with the MPDU1 and DPM disorders indicates that the
muscular dystrophy and dilated cardiomyopathy could be
shared between DOLK, DPM1 and DPM3, whereas these
features are not present in SRD5A3 and MPDU1 defects.
Fortheneurologicalandvisualproblems,itislessclearhow
to correlate symptoms with pathophysiological pathways.
Seizure are, for example, common in N-glycosylation and O-
mannosylation defects, whereas deficiency of GPI anchor
biosynthesis is associated with epilepsy as well (Krawitz et al.
2010). Ophthalmological involvement is known for both N-
glycosylation and O-mannosylation defects.
Clinical features resulting from other defects
The presence of skin involvement in SRD5A3 and DOLK
deficiencies might reflect a specific function for dolichol/
dolichol phosphate in normal skin development. It is
interesting to note that MPDU1-CDG and not DPM1 or
DPM3-CDG shows similar skin involvement, a feature
uncommonforN-glycosylationandO-mannosylationdefects.
This could suggest that the MPDU1 protein is involved in
dolichol/dolichol-P homeostasis as well.
Future therapeutic options for dolichol biosynthesis
defects
The in vitro rescue experiment of the LLO synthesis defect
in cell extracts from SRD5A3 patients indicates that the
adjustment of dolichol phosphate levels in patient cells
could theoretically correct the N-glycosylation defect.
Polyisoprenoid lipids are present in the diet, polyprenols
are abundant in mature plants in contrast with animal
tissues that possess dolichols. The contribution of dietary
dolichol to the cellular pool of dolichol has been investi-
gated in rat liver. An important part of the cholesterol
utilized in metabolic processes is supplied by the diet but
for polyisoprenoids, this contribution appeared to be quite
limited. It was found that polyisoprenoids supplied orally
were taken up through the rat gastrointestinal system; from
0.05% to a few percent of the total (Keller et al. 1982;
Jakobsson et al. 1989). The uptake efficiency depends on
the form of administration of dolichol and its incorporation
into liposomes was found to be the most efficient. The
study of the subcellular incorporation revealed that micro-
somes contain only a few percent of the labeled dietary
dolichols. Making a significant part of this exogenous
dolichol bioavailable will be an important step to consider
some therapeutic options. Some previous studies detected
that a fraction of dietary dolichol taken up by the liver was
able to be phosphorylated (i.e., about 10% ) and potentially
plays a role in protein glycosylation (Jakobsson et al. 1989)
(Chojnacki and Dallner 1983).
Conclusion
Historically,mutationsingenesencodingglycosyltransferases
in the N-glycosylation process have been described as the
cause of CDG. The identification of dolichol metabolism
defects in patients with CDG opens a new field of metabolic
diseases. They present unique opportunities to study the
functional role of a poorly understood lipid, dolichol, in
cellular processes. Besides its involvement in protein glyco-
sylation via phosphorylation to dolichol-P in the ER, this will
facilitate the identification of its role(s) in other organelles.
Several steps involved in the synthesis, recycling and
regulation of dolichol availability are still unknown. Explora-
tion of these steps in humans might allow the identification of
new inborn error of metabolisms in a spectrum overlapping
partially with the Congenital Disorders of Glycosylation.
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